Novavax
NVAX
#5751
Rank
A$1.69 B
Marketcap
A$10.40
Share price
0.73%
Change (1 day)
-19.16%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : A$2.01 Billion

According to Novavax's latest financial reports the company's total liabilities are A$2.01 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31A$3.51 B-4.85%
2023-12-31A$3.69 B-13.18%
2022-12-31A$4.25 B5.24%
2021-12-31A$4.03 B225.14%
2020-12-31A$1.24 B142.3%
2019-12-31A$0.51 B-3.92%
2018-12-31A$0.53 B3.06%
2017-12-31A$0.51 B-6.66%
2016-12-31A$0.55 B332.8%
2015-12-31A$0.12 B126.14%
2014-12-31A$56.67 M58.52%
2013-12-31A$35.75 M68.08%
2012-12-31A$21.27 M71.37%
2011-12-31A$12.41 M-20.17%
2010-12-31A$15.54 M-10.77%
2009-12-31A$17.42 M-60.52%
2008-12-31A$44.13 M36.7%
2007-12-31A$32.28 M-8.7%
2006-12-31A$35.36 M-25.5%
2005-12-31A$47.46 M-17.85%
2004-12-31A$57.77 M-10.93%
2003-12-31A$64.86 M-26.07%
2002-12-31A$87.73 M13.01%
2001-12-31A$77.63 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Agenus
AGEN
A$0.77 B-61.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A$3.27 B 62.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$1.32 B-34.27%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
A$1.25 B-37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$103.10 B 5,023.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
A$174.08 B 8,551.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$94.14 B 4,578.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
A$1.96 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
A$92.26 B 4,485.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
A$75.38 M-96.25%๐Ÿ‡บ๐Ÿ‡ธ USA